BRICS Cancer Chemotherapy Market Outlook (2021–2031)
The BRICS Cancer Chemotherapy Market size is expected to reach US$ 14,315.4 million by 2031 from US$ 6,140.1 million in 2024. The market is estimated to record a CAGR of 12.9% from 2025 to 2031.
Report Coverage
- Therapy Type: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Other Therapy Type
- Indication: Blood Cancer, Lung Cancer, Breast Cancer, Colorectum Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications
- End User: Hospital Pharmacies, Retail Pharmacies, Online Stores
US$ 6,140.1 Mn
Market size in 2024
US$ 14,315.4 Mn
Market Size by 2031
12.9%
CAGR, 2025 - 2031
2025-2031
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. BRICS Cancer Chemotherapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. BRICS Cancer Chemotherapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. BRICS Cancer Chemotherapy Market Regional Analysis
6.2 BRICS Cancer Chemotherapy Market Revenue 2021-2031 (US$ Million)
6.3 BRICS Cancer Chemotherapy Market Forecast Analysis
7. BRICS Cancer Chemotherapy Market Analysis – by Therapy Type
7.1 Alkylating Agents
- 7.1.1 Overview
- 7.1.2 Alkylating Agents: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Antimetabolites
- 7.2.1 Overview
- 7.2.2 Antimetabolites: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Anti-Tumor Antibiotics
- 7.3.1 Overview
- 7.3.2 Anti-Tumor Antibiotics: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Topoisomerase Inhibitors
- 7.4.1 Overview
- 7.4.2 Topoisomerase Inhibitors: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Mitotic Inhibitors
- 7.5.1 Overview
- 7.5.2 Mitotic Inhibitors: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Other Therapy Type
- 7.6.1 Overview
- 7.6.2 Other Therapy Type: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. BRICS Cancer Chemotherapy Market Analysis – by Indication
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectum Cancer
- 8.4.1 Overview
- 8.4.2 Colorectum Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver and Intrahepatic Bile Duct Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. BRICS Cancer Chemotherapy Market Analysis – by End User
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Stores
- 9.3.1 Overview
- 9.3.2 Online Stores: BRICS Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. BRICS Cancer Chemotherapy Market – BRICS Analysis
10.1 Overview
10.2 BRICS- 10.2.1 BRICS Cancer Chemotherapy Market Breakdown, by Key Country, 2025 and 2031 (%)
- 10.2.1.1 BRICS Cancer Chemotherapy Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 Russia: BRICS Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 Russia: BRICS Cancer Chemotherapy Market Breakdown, by Therapy Type
- 10.2.1.1.2 Russia: BRICS Cancer Chemotherapy Market Breakdown, by Indication
- 10.2.1.1.3 Russia: BRICS Cancer Chemotherapy Market Breakdown, by End User
- 10.2.1.2 Brazil: BRICS Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 Brazil: BRICS Cancer Chemotherapy Market Breakdown, by Therapy Type
- 10.2.1.2.2 Brazil: BRICS Cancer Chemotherapy Market Breakdown, by Indication
- 10.2.1.2.3 Brazil: BRICS Cancer Chemotherapy Market Breakdown, by End User
- 10.2.1.3 South Africa: BRICS Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 South Africa: BRICS Cancer Chemotherapy Market Breakdown, by Therapy Type
- 10.2.1.3.2 South Africa: BRICS Cancer Chemotherapy Market Breakdown, by Indication
- 10.2.1.3.3 South Africa: BRICS Cancer Chemotherapy Market Breakdown, by End User
- 10.2.1.4 India: BRICS Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 India: BRICS Cancer Chemotherapy Market Breakdown, by Therapy Type
- 10.2.1.4.2 India: BRICS Cancer Chemotherapy Market Breakdown, by Indication
- 10.2.1.4.3 India: BRICS Cancer Chemotherapy Market Breakdown, by End User
- 10.2.1.5 the UAE: BRICS Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.5.1 the UAE: BRICS Cancer Chemotherapy Market Breakdown, by Therapy Type
- 10.2.1.5.2 the UAE: BRICS Cancer Chemotherapy Market Breakdown, by Indication
- 10.2.1.5.3 the UAE: BRICS Cancer Chemotherapy Market Breakdown, by End User
- 10.2.1.6 and China: BRICS Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.6.1 and China: BRICS Cancer Chemotherapy Market Breakdown, by Therapy Type
- 10.2.1.6.2 and China: BRICS Cancer Chemotherapy Market Breakdown, by Indication
- 10.2.1.6.3 and China: BRICS Cancer Chemotherapy Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Johnson & Johnson
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AstraZeneca
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Pfizer Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bristol Myers Squibb
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AbbVie
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full B Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
